1. Introduction
===============

Matrix metalloproteinases (MMPs) comprise a family of Zn^2+^-binding, Ca^2+^-dependent endopeptidases whose expression and activity are upregulated in most cancers \[[@B1-cancers-04-00743],[@B2-cancers-04-00743],[@B3-cancers-04-00743],[@B4-cancers-04-00743],[@B5-cancers-04-00743]\]. Collectively, they have the capacity to degrade virtually every component of the extracellular matrix (ECM) \[[@B6-cancers-04-00743],[@B7-cancers-04-00743]\]. Most MMPs are secreted into the extracellular milieu, except for six membrane-type (MT1--MT6)-MMPs, which are anchored to the cell surface via a type I trans-membrane segment or through glycosylphosphatidylinositol \[[@B1-cancers-04-00743]\]. Under steady-state physiological conditions, the expression of MMPs in most tissues is relatively low, but it can increase dramatically under conditions of hypoxia and inflammation \[[@B3-cancers-04-00743]\] and is regulated at the transcriptional level by cytokines and growth factors \[[@B8-cancers-04-00743]\]. Previously we showed that tumor necrosis factor (TNF)-α a naturally occurring cytokine involved in normal inflammatory and immune responses, had the most pronounced stimulatory effect on the secretion of MMP-2 by normal hematopoietic stem/progenitor cells (HSPC) \[[@B9-cancers-04-00743]\]. MMP-2 is synthesized as a zymogen (proMMP-2). Activation of proMMP-2 involves binding of MT1-MMP to tissue inhibitor of metalloproteinases (TIMP)-2, and the resulting binary complex acts as a receptor for proMMP-2, which is then cleaved by a second MT1-MMP molecule generating a fully active MMP-2 \[[@B10-cancers-04-00743],[@B11-cancers-04-00743]\]. MT1-MMP not only activates proMMP-2, but also degrades ECM macromolecules (collagen I, II and III, gelatin, laminins 1 and 5, fibronectin, vitronectin, and aggrecan) by itself, releases cytokines and chemokines, and cleaves adhesion signalling receptors \[[@B12-cancers-04-00743],[@B13-cancers-04-00743],[@B14-cancers-04-00743],[@B15-cancers-04-00743]\].

Previously we demonstrated that HSPC secrete soluble MMPs, such as MMP-2 and MMP-9 after stimulation with granulocyte-colony stimulating factor (G-CSF), and others demonstrated MMP-9 secretion by G-CSF-stimulated neutrophils and suggested the role of MMP-9 in HSPC mobilization \[[@B9-cancers-04-00743],[@B16-cancers-04-00743],[@B17-cancers-04-00743]\]. MT1-MMP is also upregulated in HSPC following treatment with G-CSF, and we and others postulated that MT1-MMP facilitates the egress of HSPC from the bone marrow (BM) to peripheral blood (PB) \[[@B18-cancers-04-00743],[@B19-cancers-04-00743],[@B20-cancers-04-00743]\].We and others also reported that leukemic blasts from BM or PB of acute myeloid leukemia (AML) patients secrete soluble MMP-2 and MMP-9 and proposed that these MMPs play a role in leukemic dissemination \[[@B21-cancers-04-00743],[@B22-cancers-04-00743],[@B23-cancers-04-00743],[@B24-cancers-04-00743],[@B25-cancers-04-00743]\].

AML is a genetically heterogeneous malignancy characterized by an uncontrolled proliferation and accumulation of immature progenitors in the BM, their premature egress to the PB, and resultant dissemination into peripheral tissues. TNF-α is a pleiotropic cytokine involved in the pathogenesis of several immune disorders and hematological malignancies, including AML; a high serum TNF-α level is an adverse prognostic factor for survival in AML \[[@B26-cancers-04-00743]\]. In this work we investigated the expression of MT1-MMP in AML cells and the effect of TNF-α on it. We hypothesized that TNF-α upregulates MT1-MMP in AML cells, facilitating their egress from the BM.

2. Experimental Section
=======================

2.1. Patients and Cells
-----------------------

PB from normal donors and patients diagnosed with AML, and leukapheresis products (from patients with lymphomas in remission without BM involvement) were collected after informed consent and in accordance with the University of Alberta Health Research Ethics Board guidelines. The clinical characteristics of 43 AML patients (26 male/17 female; mean age: 54 ± 16.8 years; mean% blasts in PB: 60.1%) are presented in [Table 1](#cancers-04-00743-t001){ref-type="table"}. Light-density mononuclear cells (MNC) were separated using Ficoll-Paque PLUS (GE Healthcare, Baie d'Urfe, QC, Canada) and positively selected for CD34^+^ cells using immunomagnetic separation (Miltenyi Biotec, Auburn, CA, USA) as previously described \[[@B9-cancers-04-00743]\]. The cells were washed with Iscove's Modified Dulbecco's Medium (IMDM, Invitrogen, Burlington, ON, Canada), resuspended in serum-free media, and incubated at a concentration of 2 × 10^6^ cells/mL at 37 °C in 5% CO~2~ for 48 h. For some experiments cells were treated with 20 ng/mL recombinant human (rh) TNF-α (Peprotech, Rocky Hill, NJ, USA). The cell-conditioned media were collected and evaluated by zymography or stored at −20 °C for ELISA. The cell pellets were used for RNA isolation or lysed and analyzed by Western blot. The human myelomonocytic leukemia cell line THP-1 was obtained from the American Type Culture Collection (Rockville, MD, USA) and grown in RPMI 1640 (Invitrogen) supplemented with 10% bovine growth serum (BGS, Hyclone, ThermoFisher Scientific, Nepean, ON, Canada). Colony forming unit-fibroblast (CFU-F) cultures were established from normal BM buffy coat cells as described \[[@B27-cancers-04-00743]\]. Human umbilical vein endothelial cells (HUVEC) were cultured on gelatin-coated flasks in media consisting of M199, 10 mM L-glutamine, 250 IU/mL penicillin-streptomycin, 20% fetal calf serum (all from Invitrogen), and endothelial cell growth supplement (Collaborative Biomedical, Bedford, MA, USA). CFU-F and HUVEC were grown to sub-confluence, trypsinized, and plated in 24-well plates (1 × 10^5^ cells/mL). For co-culture experiments, PB MNC (2 × 10^6^ cells/mL) were seeded onto stromal monolayers, stimulated or not (control) with 20 ng/mL rh TNF-α and incubated for 48 h at 37 °C and 5% CO~2~. Cell-conditioned media were evaluated by zymography.

2.2. Gel-Based and Real-Time RT-PCR Analysis
--------------------------------------------

Total RNA from AML PB MNC was extracted using TRIZOL (Invitrogen) according to the manufacturer's instructions. RT-PCR reactions were carried out for MT1-MMP as described previously using GAPDH as internal control \[[@B28-cancers-04-00743]\]. PCR products were electrophoresed through 2% agarose gels containing ethidium bromide and visualized under UV light using the FluorChem Imaging System; densitometric analysis was carried out using AlphaEase FCr image analysis software (Alpha Innotech, San Leandro, CA, USA). The relative level of target mRNA was regarded as the ratio between the intensities of the target primer and GAPDH bands. Real-time RT-PCR was performed as previously described \[[@B28-cancers-04-00743]\]. Quantitative assessment of MT1-MMP mRNA levels was performed using an ABI PRISM^®^ 7000 Sequence Detection System (ABI, Foster City, CA, USA) and primer (Quantitect Hs_MMP14_1\_SG) from Qiagen (Toronto, ON, Canada). A 25 μL reaction mixture containing 12.5 μL Quantifast SYBR Green PCR master mix (Qiagen) and 10 ng of cDNA template, forward and reverse primers, were used. The threshold cycle (Ct), *i.e*., the cycle number at which the amount of amplified gene of interest reached a fixed threshold, was subsequently determined. Relative quantitation of MT1-MMP mRNA expression was calculated using the comparative Ct method. The relative quantitation value of target, normalized to an endogenous control gene and relative to a calibrator, is expressed as 2-∆∆Ct (fold difference), where ∆Ct = (Ct of target gene \[MT1-MMP\]) -- (Ct of endogenous control gene), and ∆∆Ct = (∆Ct of samples for target gene) -- (∆Ct of calibrator for the target gene).

2.3. Western Blot
-----------------

Cell pellets were sonicated in lysis buffer (1% Triton, 10 mM Tris-HCl, 150 mM NaCl, 1 mM EDTA, 1 mM EGTA, 0.5 mM phenylmethylsulphonyl fluoride, 1 mM Na~3~VO~4~, 5 μg/mL leupeptin, 5 μg/mL aprotinin, and 0.5 μg/mL pepstatin A, pH 7.3; all reagents from Sigma, Oakville, ON, Canada) and the lysates clarified by centrifugation at 18,000 × *g* for 10 min at 4 °C. Protein concentration was determined using the Bio-Rad protein assay according to the manufacturer's instructions (Bio-Rad, Hercules, CA, USA), and equal amounts of protein (30 μg) were loaded in each well. Samples were resolved in a 10% polyacrylamide gel under reducing conditions and transferred to a nitrocellulose membrane. Following blockage with 5% fat-free dried milk in Tris-buffered saline and 0.05% Tween 20, the membrane was probed with rabbit anti-human MT1-MMP polyclonal antibody (Abcam, Cambridge, MA, USA) and a secondary antibody (goat anti-rabbit, HRP-conjugated IgG, Pierce Biotechnology, Rockford, IL, USA). Chemiluminescence detection was performed using the Supersignal West Pico system (Pierce). The intensity of the bands was analyzed by densitometry using the AlphaEase FCr image analysis software (Alpha Innotech).

2.4. Trans-Matrigel Invasion Assay
----------------------------------

Cell invasion was determined using the trans-Matrigel assay as we described previously \[[@B9-cancers-04-00743],[@B29-cancers-04-00743]\]. Briefly, 13 mm polycarbonate filters (Costar/Nucleopore, Toronto, ON, Canada) were coated with 25 μg of Matrigel (Collaborative Biomedical Products) and placed between the upper and lower compartments of modified Boyden chambers (Neuro Probe Inc, Gaithersburg, MD, USA). The lower chambers contained IMDM supplemented with 0.1% BSA. AML PB MNC treated or not (control) with 20 ng/mL rh TNF-α were loaded onto the upper compartments (2 × 10^5^ cells/chamber) and incubated overnight at 37 °C, 5% CO~2~. In some experiments MNC were pre-incubated (1 h) with various concentrations of (−)-epigallocatechin 3-gallate (EGCG, Sigma) or 1 μg/mL Enbrel (Amgen, Missisauga, ON, Canada) before rh TNF-α treatment (2 h). Cells that had migrated through the Matrigel-coated filters were recovered from the lower compartments and counted using a Neubauer hemocytometer. Percentage migration was calculated from the ratio of cells recovered from the bottom chambers to the total number of cells loaded. The assay was performed at least in quadruplicate for each condition and each sample tested.
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Clinical characteristics of AML patients.

  Pt \#   Age/Sex   Diagnosis (WHO Classification)           Karyotype                                                                                                                                                                                                                                                                               Hb g/L             Plt 10^9^/L       WBC 10^9^/L       \% Blasts in PB   \% Blasts in BM   MT1-MMP
  ------- --------- ---------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ------------------ ----------------- ----------------- ----------------- ----------------- ---------
  1       23/M      AML with inv(16)                         46,XY,inv(16)(p13.1q22)\[16\]                                                                                                                                                                                                                                                           135                47                179               70                63                \+
  2       22/M      AML without maturation                   51\~54,XY,+Y,+4,+8,+10,+13,+20,+21,+22\[CP20\]                                                                                                                                                                                                                                          77                 19                166               87                94                \+
  3       75/M      Acute myelomonocytic leukemia            46,XY,del(20)(q11.2)\[6\]/47,idem,+8\[6\]/\~45,idem,+8,−10\[cp2\]                                                                                                                                                                                                                       100                28                80.9              65                62                \-
  4       44/F      Acute myelomonocytic leukemia            46,XX\[20\]                                                                                                                                                                                                                                                                             78                 98                152.4             67                62                \+
  5       58/M      AML without maturation                   46,XY\[20\]                                                                                                                                                                                                                                                                             144                33                59.8              73                83                \+
  6       23/M      AML with t(15:17)                        46,XY,t(15;17)(q22;q11)\[6\]/48,XY,der(9;15)t(9;15;17)(q22;q21),ider (17)(q10)t(15;17)(q22;q11),+ider (17)(q10)t(15;17)(q22;q21),+21\[13\]                                                                                                                                              96                 11                5.2               38                67                \+
  7       66/F      Acute myelomonocytic leukemia            46,XX\[19\]                                                                                                                                                                                                                                                                             99                 55                15.1              50                72                \-
  8       37/F      Acute monoblastic leukemia               48,XX,+8,+8\[14\]/96,idemx2\[2\]/46,XX\[1\]                                                                                                                                                                                                                                             121                190               91.8              84                81                \+
  9       17/M      Acute myelomonocytic leukemia            46,XY\[20\]                                                                                                                                                                                                                                                                             52                 27                101.2             44                51                \+
  10      78/M      AML without maturation                   46,XY\[20\]                                                                                                                                                                                                                                                                             104                58                101.4             81                88                \+
  11      36/M      AML with t(15:17)                        46,XY,t(17;19;22)(q21;p13;q13).nuc ish 15q22(PMLx2),17q21(RARAx2)(PML con RARAx1)\[225\]                                                                                                                                                                                                143                18                94                89                92                \+
  12      52/M      Acute myelomonocytic leukemia            46,XY\[20\]                                                                                                                                                                                                                                                                             89                 121               22.7              18                23                \+
  13      61/F      AML with t(15:17)                        15q22(PMLx2),17q21(RARAx2)(PML con RARAx1)\[231\]                                                                                                                                                                                                                                       83                 49                33.6              27.9              83                \+
  14      28/M      AML with t(15:17)                        46,XY,t(15;17)(q22;q21.1)\[2\]/46,XY,t(15;17)(q22;q21.1),add(20)(p?11.2)\[18\]                                                                                                                                                                                                          91                 21                21.6              84                77                \+
  15      49/F      AML without maturation                   46,XX\[20\]                                                                                                                                                                                                                                                                             126                17                145.8             94                90                \+
  16      38/M      Acute myelomonocytic leukemia            46,XY\[20\]                                                                                                                                                                                                                                                                             64                 87                44.1              49                59                \+
  17      46/M      Acute monocytic leukemia                 46,XY\[20\]                                                                                                                                                                                                                                                                             92                 16                66.7              58                89                \+
  18      77/M      AML with t(8;21)                         45,XY,−Y,t(8;21)(q22;q22)\[10\]                                                                                                                                                                                                                                                         67                 69                6.3               62                51                \+
  19      62/M      AML with 11q23 abnormality               46,XY,del(11)(q23)                                                                                                                                                                                                                                                                      123                60                71.2              80                82                \+
  20      57/M      AML with multilineage dysplasia          43,X,−Y\[20\],−3\[20\],−5\[20\],−\[20\]+8\[3\],der(3)t(3;13)(q21;q34)\[20\]add(17)(p11.2)\[20\],+mar\[4\]\[cp20\]                                                                                                                                                                       104                31                15.2              52                60                \+
  21      48/F      Acute monocytic leukemia                 46,XX\[20\]                                                                                                                                                                                                                                                                             105                120               7.1               54                79                \+
  22      50/M      Acute monocytic leukemia                 46,XY\[25\]                                                                                                                                                                                                                                                                             140                78                109.9             67                91                \+
  23      67/M      Biphenotypic acute leukemia              45\~47,XY,−2\[7\],−7\[6\], add(11)(q23)\[5\],−12 \[4\], +1\~7mar\[6\] \[cp6\]/46, XY\[1\] nuc ish 11q23 (MLLstx2) (91.0%)                                                                                                                                                               98                 72                2.5               13                49                \+
  24      72/M      AML NOC                                  ND                                                                                                                                                                                                                                                                                      84                 39                207               87                64                \+
  25      72/M      AML NOC                                  43,XY,−3,−7,der(8)t(8;15)(p23;q15), −9,−9,−13,−13,−15,−16, add(17)(p11.2),der(20)t(3;20) (q13.2;q13.1),dic(21,?)(q21;?),der (22)t(3;22)(p23;q13),−16,add(17) (p11.2),der(20)t(3;20) (q13.2;q13.1),dic(21;?)(q21;?), der(22)t(3;2)(p23;q13),+mar1, +mar2,+mar3,+mar4,+mar5, +mar6\[3\]   87                 8                 10                25                22                \+
  26      75/F      AML with maturation                      44,XX,del(5)(q15q31),−7,−18\[18\]/45,sl,+9\[3\]                                                                                                                                                                                                                                         119                46                5.8               36                33                \+
  27      47/M      AML without maturation                   45,XY,add(2)(p11.2),del(5)(q13q15),del(9)(q22),add(11)(p15),−17\[19\]                                                                                                                                                                                                                   92                 21                19.3              83                62                \+
  28      61/F      Relapsed Acute myelomonocytic leukemia   46,XX\[20\]                                                                                                                                                                                                                                                                             85                 37                112.6             87                73                \+
  29      54/F      AML with inv(16)                         46,XX,inv(16)(p13q22)\[18\]                                                                                                                                                                                                                                                             119                46                21                36                40                \+
  30      37/F      AML with maturation                      46,XX\[20\]                                                                                                                                                                                                                                                                             83                 42                188.5             91                77                \+
  31      60/F      AML with t(8;21)                         45,X,−X,t(8;21)(q22;q22)\[18\]/46, XX\[2\]                                                                                                                                                                                                                                              88                 44                8.8               65                66                \+
  32      74/F      AML without maturation                   47,XX,+13\[11\]/46,sl,−X\[4\]                                                                                                                                                                                                                                                           114                28                29.1              95                93                \+
  33      45/M      Relapsed AML with t(15;17)               46,XY,t(15;17)(q22;q21)\[10\]/46,XY,idem,del(9)(q13q22)\[6\]/46,XY\[2\]                                                                                                                                                                                                                 116                18                10.0              60                79                \+
  34      69/M      AML with multilineage dysplasia          45,XY,−7\[20\]                                                                                                                                                                                                                                                                          123                14                93.9              36                35                \+
  35      66/F      Relapsed AML                             46,X,−X,+mar\[15\]/46,XX\[4\]                                                                                                                                                                                                                                                           106                46                3.3               21                87                \+
  36      66/M      AML with multilineage dysplasia          43\~44,XY,−5\[20\],del(7)(q31)\[20\],+8\[20\],−12\[20\],−13\[20\],+add(14) (q32)\[20\],−17\[20\],18\[5\],der(8) t(12;18) (q13;p11.3)\[20\],−20\[20\], +mar\[13\],+mar1x2\[5\],1dmin\[15\]\[cp20\]                                                                                       99                 19                18                30                46                \+
  37      68/M      AML with inv(16)                         46,XY,inv(16)(p13.1q22)\[19\]                                                                                                                                                                                                                                                           94                 20                121.2             70                66                \+
  38      73/M      Relapsed AML                             46,XY\[19\]                                                                                                                                                                                                                                                                             108                56                14.8              86                88                \+
  39      64/F      AML with maturation                      47,XX,+4\[5\]/46,XX\[9\]                                                                                                                                                                                                                                                                87                 214               46.8              72                84                \+
  40      34/F      AML with maturation                      46,XX,del(9)(q13q22)\[20\]                                                                                                                                                                                                                                                              79                 29                10.2              69                76                \+
  41      55/F      AML with multilineage dysplasia          46,XX\[18\]                                                                                                                                                                                                                                                                             105                68                39.6              23                60                \+
  42      66/M      AML with multilineage dysplasia          47,XY,+8\[18\]                                                                                                                                                                                                                                                                          99                 11                79.6              88                89                \+
  43      50/F      Acute myelomonocytic leukemia            45,XX,inv(3)(q21q26),−7\[18\]                                                                                                                                                                                                                                                           94                 301               18.2              18                26                \+
                                                             **Mean ± SD (n = 43)**                                                                                                                                                                                                                                                                  **100.3 ± 20.8**   **56.6 ± 58.0**   **61.7 ± 58.2**   **60.1 ± 24.7**   **67.8 ± 20.3**   

2.5. SiRNA Electroporation
--------------------------

Small interfering (si)RNA was targeted against 21-nucleotide sequences of MT1-MMP (Dharmacon, Lafayette, CO, USA) as described \[[@B18-cancers-04-00743],[@B30-cancers-04-00743]\]. A control siRNA sequence was generated from a scrambled MT1-MMP sequence. THP-1 cells (5 × 10^6^) were electroporated with siRNA oligonucleotides (5 μg) using a nucleofector kit (Amaxa, Gaithersburg, MD, USA) according to the manufacturer's instructions and incubated for 24 h in RPMI + 10% BGS at 37 °C and 5% CO~2~. Viability of the transfected cells as determined by the trypan blue exclusion test was \>80%. The efficiency of MT1-MMP knockdown was determined by flow cytometry.

2.6. Flow Cytometric Analysis
-----------------------------

Cells were labelled with rabbit anti-human MT1-MMP antibody (Millipore) for 45 min at 4 °C, and then stained with goat anti-rabbit IgG-555 (Invitrogen). The cells were then fixed in 1% paraformaldehyde and analyzed by flow cytometry (FACS Calibur, Becton Dickinson, San José, CA, USA) and FCS Express V3 (De Novo Software, Los Angeles, CA, USA).

2.7. Zymography
---------------

The gelatinolytic activities in cell-conditioned media were assessed using sodium dodecyl sulfate-polyacrylamide gel electrophoresis as we described \[[@B9-cancers-04-00743]\]. Briefly, conditioned media were applied onto a 12% SDS-PAGE gel containing 1.5 mg/mL gelatin (Sigma) alongside media conditioned by fibrosarcoma HT-1080 cells, which exhibit both the active and pro- forms of MMP-2 and MMP-9. Clear bands at 92 kDa, 72 kDa and 62 kDa against a Coomassie blue background indicated the presence of proMMP-9, proMMP-2 and active MMP-2, respectively.

2.8. Enzyme-Linked Immunosorbent Assay (ELISA)
----------------------------------------------

TNF-α levels were measured by ELISA (Peprotech) in media conditioned by PB MNC from normal donors and AML patients as described above. Briefly, a 96-well plate was coated with 1 μg/mL anti-human TNF-α antibody and incubated overnight at room temperature. The next day, the wells were washed (0.05% Tween-20 in PBS) and block buffer (1% BSA in PBS) added. Standards and samples (100 μL) were loaded onto wells in triplicate, the plate was incubated overnight at room temperature, and after washing, detection antibody (0.5 μg/mL) was added. For color development, avidin peroxidase conjugate and 2,2\'-azino-bis(3-ethylbenzthiazoline-6-sulphonic acid (ABTS, both from Sigma) were used, and optical was density measured at 405 nm with background correction at 650 nm.

2.9. Statistical Analysis
-------------------------

Arithmetic means and standard deviations were calculated and statistical analysis of significance was carried out using a paired, 2-tailed Student's t-test with 95% confidence interval. Calculated *p*-values between data sets were considered significantly different when *p*≤ 0.05.

3. Results
==========

3.1. AML Cells Highly Express MT1-MMP in Contrast to Normal Cells
-----------------------------------------------------------------

Transcripts for MT1-MMP were found in 95% (41 out of 43) of AML samples tested ([Table 1](#cancers-04-00743-t001){ref-type="table"} and representative data in [Figure 1](#cancers-04-00743-f001){ref-type="fig"}A). MT1-MMP protein, as evaluated by Western blotting, was strongly expressed in AML cells ([Figure 1](#cancers-04-00743-f001){ref-type="fig"}B) in contrast to the weaker expression shown previously by us in normal BM MNC and CD34^+^ HSPC \[[@B18-cancers-04-00743]\]. Here we also found, using quantitative RT-PCR analysis, that both steady-state and mobilized MNC and mobilized CD34^+^ cells from normal PB have significantly lower MT1-MMP mRNA expression compared to MNC from AML PB ([Figure 1](#cancers-04-00743-f001){ref-type="fig"}C).

![(**A**) Representative gel-based RT-PCR analysis of mRNA transcripts for MT1-MMP in MNC from patients diagnosed with AML. Patient numbers ([Table 1](#cancers-04-00743-t001){ref-type="table"}) are shown on top of the gel along with positive (+) and negative (−) controls. GAPDH was used as the mRNA internal control to ensure equivalence of loading; (**B**) Western blot of MT1-MMP in lysates of MNC from representative AML patients; (**C**) MT1-MMP mRNA expression by real-time RT-PCR analysis of normal hematopoietic cells (MNC from normal (n = 4) and mobilized (m)PB (n = 4), and CD34+ cells (n = 2)) and MNC from AML (n = 7); (**D**) Zymogram of media conditioned by BM CFU-fibroblasts (**F**) or human umbilical vein endothelial cells (**E**), monocultures of MNC (cells only, c) from three representative AML patients, and their co-cultures with fibroblasts (c+F) or with endothelial cells (c+E). Media conditioned by fibrosarcoma HT-1080 cells were used as standard (Std) to indicate the positions of proMMP-9, proMMP-2, and active MMP-2.](cancers-04-00743-g001){#cancers-04-00743-f001}

3.2. Secretion of proMMPs by AML Cells and Active MMP-2 in Co-Cultures with Stromal Cells
-----------------------------------------------------------------------------------------

Previously, we reported that AML blasts (from 15 patients diagnosed with AML) express MMP-9 and MMP-2 at the gene and protein levels \[[@B22-cancers-04-00743]\]. Here, we extended our study to 43 additional patients diagnosed with AML ([Table 1](#cancers-04-00743-t001){ref-type="table"}). We confirmed that AML cells strongly secrete proMMP-9 and various levels of proMMP-2, while monocultures of stromal cells (BM fibroblasts or endothelial cells) secrete only proMMP-2 \[[@B22-cancers-04-00743]\]. Furthermore, we show here that when AML MNC were co-cultured with stromal cells, not only are the levels of proMMP-2 increased, but the active form (MMP-2) appeared ([Figure 1](#cancers-04-00743-f001){ref-type="fig"}D). Whereas active MMP-2 was undetectable in serum-free media conditioned by AML MNC alone, it was observed in co-cultures of stromal cells with MNC from two patients (\#16 and \#18) that weakly secrete proMMP-2, and from one (\#24) that did not. Moreover, we recently reported that co-cultures of fibroblasts with normal BM CD34^+^ cells, which do not secrete proMMP-2, show active MMP-2 \[[@B18-cancers-04-00743]\]. This suggests that proMMP-2 secreted by stromal cells can be activated by MT1-MMP secreted by hematopoietic cells and both are necessary for the proteolytic cascade leading to proMMP-2 activation \[[@B10-cancers-04-00743],[@B22-cancers-04-00743]\].

3.3. MT1-MMP Inhibition Reduces Cell Migration Across Reconstituted Basement Membrane
-------------------------------------------------------------------------------------

We silenced the gene expression of *MT1-MMP* in leukemic THP-1 cells with siRNA. The expression of *MT1-MMP* in transfected cells was 50% of that in cells transfected with scrambled (control) siRNA ([Figure 2](#cancers-04-00743-f002){ref-type="fig"}A). We performed co-culture experiments using THP-1 cells that were pre-treated with *MT1-MMP* siRNA and found (using zymography) significantly reduced activation of proMMP-2 in conditioned media from co-cultures of these cells with fibroblasts in comparison to co-cultures with control scrambled siRNA THP-1 cells ([Figure 2](#cancers-04-00743-f002){ref-type="fig"}B). When THP-1 cells were evaluated in the trans-Matrigel migration assay, a significant reduction in migration of the *MT1-MMP* siRNA-transfected THP-1 cells was observed compared to control (scrambled siRNA) cells ([Figure 2](#cancers-04-00743-f002){ref-type="fig"}C).

Moreover, when we exposed conditioned media from co-cultures of AML cells and fibroblasts to EGCG, an inhibitor of MT1-MMP and other MMPs \[[@B31-cancers-04-00743]\], we observed a decrease in the level of proMMP-9 and proMMP-2 as well as a dose-dependent (from 1 to 50 μM of EGCG) reduction of proMMP-2 activation ([Figure 2](#cancers-04-00743-f002){ref-type="fig"}D). EGCG had no significant effect on cell viability (data not shown). We also found that EGCG reduces the migration of AML MNC across the Matrigel in a dose-dependent manner ([Figure 2](#cancers-04-00743-f002){ref-type="fig"}E), and percentage migration was decreased by 50% to 90% using 50 μM EGCG ([Figure 2](#cancers-04-00743-f002){ref-type="fig"}F).

3.4. AML Cells Secrete TNF-α Which Upregulates MT1-MMP Expression and trans-Matrigel Migration
----------------------------------------------------------------------------------------------

Previously, we reported that rh TNF-α strongly upregulates the secretion of proMMP-2 and proMMP-9 in normal human HSPC \[[@B9-cancers-04-00743]\]. Here using ELISA, we evaluated the level of TNF-α in media conditioned by AML MNC. We found significantly higher mean levels of TNF-α in media conditioned by AML (n = 12) compared to normal MNC (n = 3) ([Figure 3](#cancers-04-00743-f003){ref-type="fig"}).

![Inhibition of MT1-MMP expression and its effect on trans-Matrigel migration. (**A**) Flow cytometric analysis of MT1-MMP expression in THP-1 cells transfected with either scrambled siRNA (control) or MT1-MMP siRNA; (**B**) Zymogram of media from monocultures and co-cultures of fibroblasts and THP-1 cells pre-treated with scrambled siRNA (control, c) or MT1-MMP siRNA; (**C**) Trans-Matrigel migration of THP-1 cells transfected with scrambled siRNA (control) and MT1-MMP siRNA. The assay was performed at least in quadruplicate for each condition; (**D**) MMP activities in media conditioned by co-cultures of AML MNC from a representative patient (Pt. No. 13) and CFU-fibroblasts (**F**) in the presence of increasing doses of EGCG; (**E**) Dose-dependence of inhibition by EGCG of trans-Matrigel migration of MNC; (**F**) Percentage migration of MNC from two representative AML patients in the presence or absence (control) of 50 μM EGCG. The assay was performed at least in quadruplicate for each condition and each sample. \* *p*≤ 0.05 relative to control.](cancers-04-00743-g002){#cancers-04-00743-f002}

![TNF-α levels in media conditioned by MNC from normal donors and AML patients as evaluated by ELISA. \* *p*≤ 0.05.](cancers-04-00743-g003){#cancers-04-00743-f003}

Having confirmed an earlier report that TNF-α is elevated in AML \[[@B26-cancers-04-00743]\], we next examined whether TNF-α has any effect on *MT1-MMP* mRNA expression. We found that rh TNF-α increased (up to 1.4-fold by gel-based RT-PCR and up to more than 3-fold by quantitative RT-PCR) the expression of *MT1-MMP* transcripts in MNC from AML patients ([Figure 4](#cancers-04-00743-f004){ref-type="fig"}A,B, respectively). The expression of total MT1-MMP protein, as evaluated by Western blotting, was increased up to 1.4-fold ([Figure 4](#cancers-04-00743-f004){ref-type="fig"}C). The moderate increases in MT1-MMP gene and protein expression upon TNF-α stimulation could be explained by the fact that these cells had been pre-exposed to endogenously produced TNF-α. When we stimulated AML cells with rh TNF-α under co-culture conditions with fibroblasts, we observed a very strong activation of proMMP-2, although TNF-α barely affected the secretion of proMMP-2 by BM stromal fibroblasts or AML blasts in monocultures ([Figure 4](#cancers-04-00743-f004){ref-type="fig"}D). In addition, we observed that TNF-α also increased proMMP-9 secretion (5.5-fold) when AML MNC were co-cultured with fibroblasts.

Moreover, rh TNF-α stimulated the trans-Matrigel migration of AML MNC. This trans-Matrigel migration was inhibited by EGCG, as well as by Enbrel, a soluble TNF-receptor fusion protein that blocks TNF-α. Together EGCG and Enbrel had additive inhibitory effects on the trans-Matrigel migration of AML MNC stimulated with TNF-α ([Figure 4](#cancers-04-00743-f004){ref-type="fig"}E).

![(**A**) Gel-based RT-PCR analysis of *MT1-MMP* transcript obtained from representative AML patient samples stimulated or not (control, c) with 20 ng/mL rh TNF-α (+T). *GAPDH* was used as mRNA control to ensure equivalence of loading. The numbers at the bottom of the gel represent fold-increase in expression of *MT1-MMP* relative to control as determined by densitometric analysis; (**B**) Quantitative RT-PCR analysis of *MT1-MMP* mRNA expression in MNC from representative AML patients as well as normal hematopoietic cells (CD34^+^ cells and PB MNC) stimulated or not (control) with rh TNF-α; (**C**) Western blot analysis of MT1-MMP expression in MNC from representative AML patients stimulated or not with rh TNF-α. The numbers at the bottom of the gel represent fold-increase in expression of MT1-MMP relative to control; (**D**) Zymogram of media from fibroblasts (**F**) or AML MNC with or without (control) rh TNF-α and from a co-culture of fibroblasts and MNC from a representative AML patient (Pt. No. 34), stimulated or not with rh TNF-α. Media conditioned by fibrosarcoma HT-1080 cells were used as standard (Std) to indicate the positions of proMMP-9, proMMP-2 and active MMP-2; (**E**) The TNF-α-stimulated trans-Matrigel migration of MNC from a representative AML patient was inhibited by the TNF-α-receptor fusion protein, Enbrel (Enb), and by the MT1-MMP inhibitor EGCG (EG) alone and in combination.](cancers-04-00743-g004){#cancers-04-00743-f004}

4. Discussion
=============

Early attempts to identify MMPs responsible for mediating tumor invasion focused on soluble MMPs (particularly MMP-2 and MMP-9), and expression of these MMPs correlated with the neoplastic phenotype \[[@B32-cancers-04-00743]\]. Previously, we and others evaluated the expression of MMP-2 and -9 and TIMP-2 in patients with AML and proposed their role in the dissemination of leukemic blasts \[[@B21-cancers-04-00743],[@B22-cancers-04-00743],[@B23-cancers-04-00743],[@B24-cancers-04-00743],[@B25-cancers-04-00743],[@B33-cancers-04-00743]\]. Because MMP-2 and MMP-9 are synthesized as latent enzymes, here we focused on MT1-MMP, the most common physiological activator of proMMP-2. However, we found that despite the expression of both MT1-MMP and TIMP-2, which are the putative components of proMMP-2 activation, active MMP-2 was undetectable in serum-free media conditioned by AML MNC alone. Also, BM stromal cells (fibroblasts), although expressing MT1-MMP as well as TIMP-2, secrete only proMMP-2 and no active MMP-2, as reported by us previously \[[@B22-cancers-04-00743]\]. We evaluated 43 patients diagnosed with AML and report here the expression of MT1-MMP in 41 out of 43 (95%) patients studied ([Table 1](#cancers-04-00743-t001){ref-type="table"}). Using gene silencing with *MT1-MMP* siRNA, we demonstrated a functional link between MT1-MMP activity and *in vitro* migration of leukemic THP-1 cells across reconstituted basement membrane. Consistent with our data, it was reported that inhibition of MMP-2 and MT1-MMP by siRNA substantially impairs the migration of a highly invasive human acute monocytic leukemia cell line SHI-1 \[[@B34-cancers-04-00743]\]. Thus, our data present further evidence for a role of MT1-MMP in the migration and dissemination of leukemic cells.

It has been shown that MT1-MMP siRNA-treated tumor cells are unable to penetrate three-dimensional collagen barriers \[[@B35-cancers-04-00743]\]. Furthermore, using a highly selective humanized anti-catalytic MT1-MMP monoclonal antibody (DX-2400) in a MDA-MB231 xenograft model, it was demonstrated that MT1-MMP is the dominant proteolytic enzyme responsible for tumor invasion and metastasis \[[@B36-cancers-04-00743]\]. High concentrations of MT1-MMP on the cell membranes of metastatic cells were shown by high-resolution multimodal microscopy to drive the dissemination of cancer cells into adjacent normal tissue \[[@B37-cancers-04-00743]\]. Focal basement membrane remodelling is required to generate a conduit permissive for cell passage across ECM barriers, and the membrane-anchored MT-MMPs are suitably localized at the leading edge of migrating cells \[[@B38-cancers-04-00743]\]. MT1-MMP is internalized in caveolae, cholesterol-rich membrane microdomains \[[@B13-cancers-04-00743],[@B39-cancers-04-00743]\], and is readily available for rapid surface localization in invasive membrane protrusions called invadopodia \[[@B15-cancers-04-00743]\]. Recruitment of MT1-MMP to invadopodia of tumor cells occurs during the metastatic process, where it enhances local ECM degradation and facilitates tumor cell migration and invasion. Our findings here suggest that the mechanisms by which leukemic cells disseminate may be similar to those utilized by tumor cells.

We also showed that TNF-α-stimulated AML cells co-cultured with fibroblasts are more potent activators of proMMP-2 than unstimulated cells and further support the role of the microenvironment for providing cues permissive for disease progression \[[@B40-cancers-04-00743]\]. TNF-α is expressed on a variety of cells as a membrane-bound precursor (pro-TNF-α), which can be converted to its active form through proteolytic cleavage by several MMPs including MMP-2, MMP-9 and MT1-MMP \[[@B41-cancers-04-00743],[@B42-cancers-04-00743],[@B43-cancers-04-00743]\]. We confirmed that TNF-α is constitutively secreted by AML cells and its levels are significantly higher in media conditioned by AML cells compared to normal controls. Consistent with these findings, TNF-α mRNA expression was reported to be higher in BM cells from *de novo* AML patients compared to normal controls \[[@B44-cancers-04-00743]\].

The soluble TNF-α receptor fusion protein etanercept (Enbrel) acts as a competitive inhibitor that blocks the interaction of TNF-α with its cell surface receptors and consequently, activation of target cells, but had limited activity as a therapeutic agent in AML patients treated with chemotherapy \[[@B45-cancers-04-00743]\]. As MMPs mediate TNF-α processing and secretion \[[@B41-cancers-04-00743]\], it is possible that inhibition of these processes by MMP inhibitors could attenuate TNF-α activation and secretion. Moreover, given that TNF-α contributes to progression of several cancers \[[@B46-cancers-04-00743]\], reducing TNF-α levels in AML using MMP inhibitors may dampen the inflammatory milieu in the BM microenvironment; however further studies are required to confirm it. The green tea catechins, such as EGCG, have been extensively investigated for their antioxidant and anti-inflammatory capabilities, particularly as chemopreventive agents by suppressing MMP expression \[[@B43-cancers-04-00743]\]. Here we showed that a combination of the TNF-α antagonist Enbrel with EGCG diminishes the in vitro invasion of AML cells across reconstituted basement membrane by almost 80%. The widespread involvement of MMPs in physiological processes renders broad spectrum inhibitors of MMPs clinically undesirable due to inefficacy and adverse side effects \[[@B47-cancers-04-00743]\]; however, targeting MT1-MMP, which we show here to be upregulated under inflammatory conditions (e.g., high TNF-α levels), should be further investigated.

5. Conclusions
==============

In conclusion, our findings that high TNF-α levels secreted by AML cells contribute to an upregulation in MT1-MMP expression, and enhanced proMMP-2 activation leading to increased trans-Matrigel invasion by these cells indicate a potential synergistic relationship between MT1-MMP and TNF-α. As MMPs are recognized as a therapeutic target for many cancers \[[@B2-cancers-04-00743],[@B48-cancers-04-00743]\], our work indicates that despite the karyotypic heterogeneity among AML patients, MT1-MMP expression appears to be almost ubiquitous and suggests that targeting of MT1-MMP as part of a combinatorial approach should be investigated in designing future treatments for AML.
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